Patents by Inventor Mitchell C. Sanders

Mitchell C. Sanders has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7566564
    Abstract: Described herein are zymogens, methods of use for zymogens, and devices that incorporate zymogens. The zymogens include a substrate and an enzyme. The substrate can inhibit the enzyme and is a target for a protein produced by a microorganism. When the substrate is modified by a protein produced by a microorganism, the enzyme is activated. The zymogens can be used to amplify detection assays.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: July 28, 2009
    Assignee: Ethicon, Inc.
    Inventors: Gerard J. Colpas, Shite Sebastian, Mitchell C. Sanders
  • Patent number: 7282572
    Abstract: A method for expressing proteins as a fusion chimera with a domain of p26 or alpha crystallin type proteins to improve the protein stability and solubility when over expressed in bacteria such as E. coli is provided. Genes of interest are cloned into the multiple cloning site of the Vector System just downstream of the p26 or alpha crystallin type protein and a thrombin cleavage site. Protein expression is driven by a strong bacterial promoter (TAC). The expression is induced by the addition of 1 mM IPTG that overcomes the lac repression (lac Iq). The soluble recombinant protein is purified using a fusion tag.
    Type: Grant
    Filed: May 23, 2006
    Date of Patent: October 16, 2007
    Assignee: ECI Biotech, Inc.
    Inventor: Mitchell C. Sanders
  • Patent number: 7244583
    Abstract: A device and method for detecting the presence or absence of a prokaryotic microorganism are provided, comprising the steps of identifying a protein, such as a microbial-specific protease that characterizes the presence of a specific prokaryotic microbe and thereby provides a marker for that microbe; detecting the protease that is a marker for the presence of a specific prokaryotic microbe by cleaving a substrate when the protease is present; and signaling the presence of that protease when cleavage has occurred. More specifically, the method comprises identifying at least one outer membrane protein or a secreted protein that is unique to a particular microbial pathogen such as for example Listeria monocytogenes and that is substrate specific.
    Type: Grant
    Filed: January 14, 2005
    Date of Patent: July 17, 2007
    Assignee: ECI Biotech Inc.
    Inventor: Mitchell C. Sanders
  • Patent number: 7074757
    Abstract: A method for expressing proteins as a fusion chimera with a domain of p26 or alpha crystallin type proteins to improve the protein stability and solubility when over expressed in bacteria such as E. coli is provided. Genes of interest are cloned into the multiple cloning site of the Vector System just downstream of the p26 or alpha crystallin type protein and a thrombin cleavage site. Protein expression is driven by a strong bacterial promoter (TAC). The expression is induced by the addition of 1 mM IPTG that overcomes the lac repression (lac Iq). The soluble recombinant protein is purified using a fusion tag.
    Type: Grant
    Filed: March 1, 2005
    Date of Patent: July 11, 2006
    Assignee: Expressive Constructs, Inc.
    Inventor: Mitchell C. Sanders
  • Patent number: 6861403
    Abstract: A method for expressing proteins as a fusion chimera with a domain of p26 or alpha crystallin type proteins to improve the protein stability and solubility when over expressed in bacteria such as E. coli is provided. Genes of interest are cloned into the multiple cloning site of the Vector System just downstream of the p26 or alpha crystallin type protein and a thrombin cleavage site. Protein expression is driven by a strong bacterial promoter (TAC). The expression is induced by the addition of 1 mM IPTG that overcomes the lac repression (lac Iq). The soluble recombinant protein is purified using a fusion tag.
    Type: Grant
    Filed: May 3, 2001
    Date of Patent: March 1, 2005
    Assignee: Expressive Constructs, Inc.
    Inventor: Mitchell C. Sanders
  • Publication number: 20040259252
    Abstract: A molecular expression and cloning system which employs an oligonucleotide which converts a low copy number plasmid into a more efficient high copy number plasmid is disclosed. A high copy number plasmid can be used to facilitate more efficient expression or co-expression of proteins.
    Type: Application
    Filed: July 2, 2004
    Publication date: December 23, 2004
    Inventors: Mitchell C. Sanders, Maureen A. Hamilton
  • Publication number: 20030096315
    Abstract: A device and method for detecting the presence or absence of a prokaryotic microorganism are provided, comprising the steps of identifying a protein, such as a microbial-specific protease that characterizes the presence of a specific prokaryotic microbe and thereby provides a marker for that microbe; detecting the protease that is a marker for the presence of a specific prokaryotic microbe by cleaving a substrate when the protease is present; and signaling the presence of that protease when cleavage has occurred. More specifically, the method comprises identifying at least one outer membrane protein or a secreted protein that is unique to a particular microbial pathogen such as for example Listeria monocytogenes and that is substrate specific.
    Type: Application
    Filed: May 3, 2001
    Publication date: May 22, 2003
    Inventor: Mitchell C. Sanders
  • Publication number: 20020142384
    Abstract: A method for expressing proteins as a fusion chimera with a domain of p26 or alpha crystallin type proteins to improve the protein stability and solubility when over expressed in bacteria such as E. coli is provided. Genes of interest are cloned into the mutiple cloning site of the pROTECT Vector System just downstream of the p26 or alpha crystallin type protein and a thrombin cleavage site. Protein expression is driven by a strong bacterial promoter (TAC). The expression is induced by the addition of 1 mM IPTG that overcomes the lac repression (lac Iq). The soluble recombinant protein is purified using a fusion tag.
    Type: Application
    Filed: May 3, 2001
    Publication date: October 3, 2002
    Inventor: Mitchell C. Sanders